<DOC>
	<DOC>NCT00189657</DOC>
	<brief_summary>The main objective of this randomized trial is to compare 5FU/LV (Mayo-Clinic regimen or LV5FU2) to LV5FU2 + irinotécan in patients with resected B2 and C rectal cancer. Preoperative radiotherapy is recommended but not mandatory. Main endpoint is disease free survival. Secondary endpoint are overall survival, time to local recurrence, time to distant metastases, and tolerance. A total of 600 patients will be included in the trial.</brief_summary>
	<brief_title>5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>rectal adenocarcinoma R0 surgery T3, N0, M0 or T4, N0, M0 or N1,2, M0 chemotherapy can be started within 8 weeks after surgery Age &gt; 18 Performance status ECOG &lt; 3 preoperative radiotherapy allowed preoperative chemotherapy with 5FU +/ LV allowed Neutrophiles &gt; 1 500/mm3; Pl. &gt; 100 000/mm3 Transaminases &lt; 2 x UNL; Alcalines Phosphatases &lt; 2 x UNL; Bili &lt; 1.1 UNL creatininemia &lt; 120 µmol/l and/or clearance of creatininemia &gt; 60 ml/mn Written informed consent before inclusion postoperative radiotherapy Distant metastases Contraindication to any drug contained in the chemotherapy regimens Any serious active disease or comorbid medical condition including digestive inflammatory disease Gilbert disease severe toxicity of radiotherapy Pregnancy or breast feeding Absence of contraception in non menopausal women Adult patient unable to give informed consent because of intellectual impairment Concomitant participation to another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>